Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IlluminaXSWX:ILMN 76 3-Year EPS without NRI Growth Rate is 31.70% as of Jun. 2026, which is 39% above its 10-year median of 22.80. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF107.32. The stock has 7 warning signs investors should review. Among 158 Medical Diagnostics & Research companies, Illumina ranks better than 70.89% on this metric.
During the past 12 months, Illumina's average EPS without NRI Growth Rate was 23.80% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 31.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -55.30% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -5.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Illumina was 449.60% per year. The lowest was -89.10% per year. And the median was 22.80% per year.
Illumina (XSWX:ILMN) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Illumina 3-Year EPS without NRI Growth Rate Related Terms
XSWX:ILMN vs MTD, DGX, LH: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Illumina's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Illumina's 3-Year EPS without NRI Growth Rate falls into.
Illumina 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 31.70% mean?
Illumina (XSWX:ILMN) has a 3-Year EPS without NRI Growth Rate of 31.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Illumina and its competitors. This is 39% above median its historical median of 22.80. According to the industry distribution chart, Illumina ranks #46 out of 158 companies in the Medical Diagnostics & Research industry, placing it in the top 29.1%.
Is Illumina's 3-Year EPS without NRI Growth Rate too high?
Illumina's current 3-Year EPS without NRI Growth Rate of 31.70% is 39% above median its 10-year median of 22.80. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 11.10. Illumina's value of 31.70% is 185.6% above this industry median. Based on the distribution chart, Illumina ranks #46 out of 158 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's 3-Year EPS without NRI Growth Rate compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #46 out of 158 companies for 3-Year EPS without NRI Growth Rate. This puts Illumina in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.10. Illumina's value of 31.70% is 185.6% above this benchmark. While the company's 10-year median is 22.80 vs. the industry median of 11.10, Illumina has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 11.10, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current 3-Year EPS without NRI Growth Rate of 31.70% is 185.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Illumina and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current 3-Year EPS without NRI Growth Rate is 31.70%, which is 39% above median its own 10-year median of 22.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current 3-Year EPS without NRI Growth Rate of 31.70%. The stock's GF Value™ is CHF107.32, compared to a current price of CHF155.14 — trading 44.6% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 31.70%, which is 39% above median its 10-year median of 22.80 and 185.6% above the Medical Diagnostics & Research industry median of 11.10. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current 3-Year EPS without NRI Growth Rate is 31.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF155.14 is trading 44.6% above its estimated GF Value™ of CHF107.32.
Key valuation signals for XSWX:ILMN:
3-Year EPS without NRI Growth Rate: 31.70% (39% above median its 10-year median of 22.80)
GF Value™: CHF107.32 vs. price of CHF155.14 (44.6% above fair value)
Industry Position: 185.6% above the Medical Diagnostics & Research median (#46 of 158)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
